Proceedings of the 2015 Winter Simulation Conference
L. Yilmaz, W. K. V. Chan, I. Moon, T. M. K. Roeder, C. Macal, and M. D. Rossetti, eds

UNDERSTAND RISKS IN DRUG DEVELOPMENT THROUGH SIMULATION

Fei Chen
Janssen Pharmaceutical Research & Development
Johnson & Johnson
902 Rt 202 S.
Raritan, NJ 08812

ABSTRACT

Running a clinical trial program that leads to the approval of a new medical compound takes a tremendous amount of investment. The probability of success is low, and properly evaluating and understanding this risk is crucially important to drug companies with large portfolios. Simulation-based modeling plays an increasingly critical role in this endeavor. In this talk, I will discuss how simulation guided design can significantly reduce cost of a trial through assessing risk-benefit trade-offs from a drug safety perspective.